BERKELEY, Calif., Nov. 9, 2011 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced its financial results for the third quarter ended September 30, 2011. XOMA had total revenues of $16.2 million in the third quarter of 2011, compared with $10.9 million in the third quarter of 2010. Third quarter 2011 revenue includes $5.9 million from Les Laboratoires Servier under the companies’ collaboration agreement for gevokizumab (XOMA 052) entered into in December 2010.
